# Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/liraglutide-once-a-day-versus-exenatide-twice-a-day-for-type-2-diabetes-a-26/

## Facts

| Field | Value |
| --- | --- |
| Author Names | John B. Buse,Julio Rosenstock,Giorgio Sesti,Wolfgang E. Schmidt,Eduard Montanya,Jason Brett,Marcin Zychma,Lawrence Blonde |
| Citations | 1,499 |
| DOI | 10.1016/s0140-6736(09)60659-0 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2170606300 |
| PMID | 19515413 |
| Type | article |
| Year | 2009 |

## Paper authors

- [John B. Buse](https://scholariq.org/researchers/john-b-buse/)
- [Julio Rosenstock](https://scholariq.org/researchers/julio-rosenstock/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.